Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial

Background: Signs of feeding intolerance are common in formula-fed infants. We evaluated the clinical response to a partially hydrolyzed 100% whey protein formula with high sn -2 palmitate and reduced lactose (FA) and to an alpha-lactalbumin-enriched whey-predominant intact protein formula with full...

Full description

Bibliographic Details
Main Authors: Boosba Vivatvakin MD, Elvira Estorninos MD, Reyin Lien MD, Hung Chang Lee MD, Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM, Jowena Lebumfacil PhD, Colin I Cercamondi PhD, Sheri Volger PhD, RDN
Format: Article
Language:English
Published: SAGE Publishing 2020-09-01
Series:Global Pediatric Health
Online Access:https://doi.org/10.1177/2333794X20954332
id doaj-bc4317ae34c8460881746e0635fe1cf1
record_format Article
spelling doaj-bc4317ae34c8460881746e0635fe1cf12020-11-25T03:14:02ZengSAGE PublishingGlobal Pediatric Health2333-794X2020-09-01710.1177/2333794X20954332Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized TrialBoosba Vivatvakin MD0Elvira Estorninos MD1Reyin Lien MD2Hung Chang Lee MD3Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM4Jowena Lebumfacil PhD5Colin I Cercamondi PhD6Sheri Volger PhD, RDN7Chulalongkorn University, Bangkok, ThailandAsian Hospital and Medical Center, Muntinlupa City, PhilippinesChang Gung Memorial Hospital, Taoyuan, TaiwanMackay Memorial Hospital, Taipei, TaiwanThe Chinese University of Hong Kong, Shatin, N.T., Hong KongWyeth Nutrition, Makati City, Manila, PhilippinesNestlé Product Technology Center – Nutrition, Société des Produits Nestlé S.A., Vevey, SwitzerlandNestlé Product Technology Center – Nutrition, Société des Produits Nestlé S.A., Vevey, SwitzerlandBackground: Signs of feeding intolerance are common in formula-fed infants. We evaluated the clinical response to a partially hydrolyzed 100% whey protein formula with high sn -2 palmitate and reduced lactose (FA) and to an alpha-lactalbumin-enriched whey-predominant intact protein formula with full lactose (FB) in healthy full-term infants with parent-reported signs of feeding intolerance. Methods: In a double-blind, parallel-group trial in 6 Asian study centers, exclusively formula-fed infants aged 30 to 90 days, whose parents reported fussiness-crying for ≥2 hours/day plus gassiness and/or stooling difficulty, and intended to switch formula, were randomly assigned to FA (n = 130) or FB (n = 129) for 14 days. Primary endpoint was daily duration of fussiness-crying. Secondary endpoints included gassiness, spitting-up, vomiting, sleep pattern, Infant Gastrointestinal Symptom Questionnaire (IGSQ) Index, infant temperament and maternal anxiety. Results: Mean ± SE minutes/day of fussiness-crying in the 256 analyzed infants (FA, n = 127 and FB, n = 129) substantially decreased from baseline to study end in FA (291 ± 14 to 140 ± 8; –52%, P  < .001), and FB (313 ± 14 to 153 ± 11, –51%, P  < .001) with no difference between groups. Similarly, gassiness, spitting-up, vomiting and sleep pattern significantly improved by study end for both formulas. Mean ± SE IGSQ index scores significantly decreased from baseline to study end (FA: 44.5 ± 0.9 to 28.6 ± 0.7; FB: 44.5 ± 0.8 to 29.0 ± 0.7; P  < .001) with no differences between groups. Infant temperament and maternal anxiety also improved significantly in both groups by study end. Conclusion: Switching from standard, full-lactose, intact whey/casein infant formulas to either study formula resulted in an improvement of gastrointestinal symptoms and associated behaviors in infants with signs of feeding intolerance. Trial Registration: https://clinicaltrials.gov , NCT02021058https://doi.org/10.1177/2333794X20954332
collection DOAJ
language English
format Article
sources DOAJ
author Boosba Vivatvakin MD
Elvira Estorninos MD
Reyin Lien MD
Hung Chang Lee MD
Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM
Jowena Lebumfacil PhD
Colin I Cercamondi PhD
Sheri Volger PhD, RDN
spellingShingle Boosba Vivatvakin MD
Elvira Estorninos MD
Reyin Lien MD
Hung Chang Lee MD
Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM
Jowena Lebumfacil PhD
Colin I Cercamondi PhD
Sheri Volger PhD, RDN
Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
Global Pediatric Health
author_facet Boosba Vivatvakin MD
Elvira Estorninos MD
Reyin Lien MD
Hung Chang Lee MD
Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM
Jowena Lebumfacil PhD
Colin I Cercamondi PhD
Sheri Volger PhD, RDN
author_sort Boosba Vivatvakin MD
title Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
title_short Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
title_full Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
title_fullStr Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
title_full_unstemmed Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
title_sort clinical response to two formulas in infants with parent-reported signs of formula intolerance: a multi-country, double-blind, randomized trial
publisher SAGE Publishing
series Global Pediatric Health
issn 2333-794X
publishDate 2020-09-01
description Background: Signs of feeding intolerance are common in formula-fed infants. We evaluated the clinical response to a partially hydrolyzed 100% whey protein formula with high sn -2 palmitate and reduced lactose (FA) and to an alpha-lactalbumin-enriched whey-predominant intact protein formula with full lactose (FB) in healthy full-term infants with parent-reported signs of feeding intolerance. Methods: In a double-blind, parallel-group trial in 6 Asian study centers, exclusively formula-fed infants aged 30 to 90 days, whose parents reported fussiness-crying for ≥2 hours/day plus gassiness and/or stooling difficulty, and intended to switch formula, were randomly assigned to FA (n = 130) or FB (n = 129) for 14 days. Primary endpoint was daily duration of fussiness-crying. Secondary endpoints included gassiness, spitting-up, vomiting, sleep pattern, Infant Gastrointestinal Symptom Questionnaire (IGSQ) Index, infant temperament and maternal anxiety. Results: Mean ± SE minutes/day of fussiness-crying in the 256 analyzed infants (FA, n = 127 and FB, n = 129) substantially decreased from baseline to study end in FA (291 ± 14 to 140 ± 8; –52%, P  < .001), and FB (313 ± 14 to 153 ± 11, –51%, P  < .001) with no difference between groups. Similarly, gassiness, spitting-up, vomiting and sleep pattern significantly improved by study end for both formulas. Mean ± SE IGSQ index scores significantly decreased from baseline to study end (FA: 44.5 ± 0.9 to 28.6 ± 0.7; FB: 44.5 ± 0.8 to 29.0 ± 0.7; P  < .001) with no differences between groups. Infant temperament and maternal anxiety also improved significantly in both groups by study end. Conclusion: Switching from standard, full-lactose, intact whey/casein infant formulas to either study formula resulted in an improvement of gastrointestinal symptoms and associated behaviors in infants with signs of feeding intolerance. Trial Registration: https://clinicaltrials.gov , NCT02021058
url https://doi.org/10.1177/2333794X20954332
work_keys_str_mv AT boosbavivatvakinmd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT elviraestorninosmd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT reyinlienmd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT hungchangleemd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT kamlunellishonmbbsmdfaapfccm clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT jowenalebumfacilphd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT colinicercamondiphd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
AT sherivolgerphdrdn clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial
_version_ 1724644953407094784